Ronald Marcellus Knegtel

This inventor holds 101 USPTO granted patents and 24 published patent applications, plus 4 CIPO patents and 27 EPO patents, primarily in Protein Kinase Inhibitors (CPC class C07D487-04). Top assignees: Vertex Pharmaceuticals, Inc., Merck Patent Gmbh, Other. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald Marcellus Knegtel. Retrieved from https://idiyas.com/inventor/ronald-marcellus-knegtel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 101 (Patent Applications = 24)

% Patents Active = 29.7

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 27 (Patent Applications = 25)

Average Co-Inventor Count = 6.9

ph-index = 25

Forward Citations = 2,327(Granted Patents)

Forward Citations (Not Self Cited) = 2,072(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Abingdom Oxon, GB (2003)
Abingdom, GB (2003 - 2008)
Abingdon, Oxfordshire, GB (2010)
Abingdon Oxfordshire, GB (2010)
Oxfordshire, GB (2012)
Milton Park, GB (2012)
Abindgon, GB (2009 - 2013)
Abingdon, GB (2003 - 2024)

Company Filing History:

100 out of 1,169

Vertex Pharmaceuticals, Inc.

1 out of 834,708

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

ATR Kinase

GCN2 Inhibitors

Tetrahydrofuran

Pyrazines

Thiazoles

Imidazoles

Pyrimidine Derivatives

Carboxamides

Triazole Compounds

Pyrazolopyridine

101 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662470 - Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels (2026-06-23),

2. 12258333 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2025-03-25),

3. 12247021 - Substituted tetrahydrofurans as modulators of sodium channels (2025-03-11),

4. 12187731 - Compounds useful as inhibitors of ATR kinase (2025-01-07),

5. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

6. 11919887 - Substituted tetrahydrofurans as modulators of sodium channels (2024-03-05),

7. 11834441 - Substituted tetrahydrofurans as modulators of sodium channels (2023-12-05),

8. 11827627 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2023-11-28),

9. 11370798 - Compounds useful as inhibitors of ATR kinase (2022-06-28),

10. 11117900 - Compounds useful as inhibitors of ATR kinase (2021-09-14),

11. 10988477 - GCN2 inhibitors and uses thereof (2021-04-27),

12. 10961232 - Substituted pyrazines as ATR kinase inhibitors (2021-03-30),

13. 10800781 - Compounds useful as inhibitors of ATR kinase (2020-10-13),

14. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

15. 10787452 - Compounds useful as inhibitors of ATR kinase (2020-09-29),

Title: Ronald Marcellus Knegtel: A Visionary Innovator in the World of Technology

Introduction:

Ronald Marcellus Knegtel is a prominent inventor based in Abingdon, GB, known for his relentless pursuit of innovation and commitment to creating a better future through his groundbreaking inventions. With a staggering 96 patents to his name, Knegtel's work has not only pushed the boundaries of technological advancements but has also inspired others to strive for excellence in their own endeavors.

Latest Patents:

One of Knegtel's latest patents includes "Substituted tetrahydrofurans as modulators of sodium channels." This compound, along with its pharmaceutically acceptable salts, serves as an inhibitor of sodium channels and shows potential in the treatment of various disorders, including pain. His dedication to developing such novel compounds showcases his innovative spirit and determination to make a significant impact on the field of technology and healthcare.

Career Highlights:

Throughout his illustrious career, Knegtel has worked with renowned companies such as Vertex Pharmaceuticals, Inc., and Merck Patent GmbH. His time at these institutions allowed him to further hone his skills as an inventor and collaborate with leading experts in the industry. Knegtel's contributions to these organizations have been instrumental in driving innovation and fostering technological advancements.

Collaborations:

In his journey towards innovation, Knegtel has had the privilege of collaborating with exceptional individuals such as Jean-Damien Charrier and David Kay. These talented coworkers have played a crucial role in shaping Knegtel's inventive process, leading to the development of groundbreaking technologies that have left a lasting impact on the world.

Conclusion:

Ronald Marcellus Knegtel's visionary approach to innovation and his unwavering dedication to creating groundbreaking inventions have rightfully earned him a place among the stalwarts of the technology industry. His remarkable journey serves as a testament to the power of persistence, creativity, and collaboration in driving meaningful change and shaping a better future for generations to come.

Profile summary based on public USPTO records.